Adaptive Biotechnologies announces new collaboration with BeiGene

Adaptive Biotechnologies (ADPT) announced a multi-year, global translational collaboration with BeiGene (BGNE) to assess minimal residual disease using clonoSEQ assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. “Adaptive is pleased to partner with BeiGene to support the clinical development and potential regulatory approval of their investigational therapies in lymphoid malignancies,” said Mary Pat Lancelotta, Senior Vice President, BioPharma at Adaptive Biotechnologies. “MRD status has strong prognostic value, and by integrating the measure into clinical studies our partners can more quickly and efficiently evaluate and advance novel therapeutics.” This multi-year agreement will cover existing and future programs and adds to Adaptive’s growing list of translational collaborations with biopharmaceutical companies. As part of the collaboration, MRD status based on Adaptive’s clonoSEQ assay may be used as an endpoint in certain clinical trials to assess the depth and duration of response to BeiGene’s investigational medicines in patients with lymphoid malignancies.